ERBB2 and gastric cancer: Due to complex molecular mechanisms and clinical heterogeneity, clinical outcomes for patients with advanced gastric cancer remain poor, with a 5-year survival of 5–20% and a median overall survival (OS) of 10 months [2].To date, only two targeted therapies, treatment with trastuzumab (HER2 inhibitor) or ramucirumab (VEGFR2 inhibitor), have been approved for the treatment of advanced gastric cancer in patients carrying relevant biomarkers and development of more targeted therapeutic strategies for gastric cancer is needed.